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ABSTRACT 
 
Introduction: In patients with liver cirrhosis, the contribution of inherited and acquired 
prothrombotic disorders in the development of non-malignant PVT is inconclusive. The 
purpose of this study was to examine the prevalence of inherited and acquired 
thrombophilia in cirrhotic non-malignant PVT at our center. As secondary aims we 
explored the influence these disorders on the clinical presentation of PVT and response 
to anticoagulation. 
Methods: we conducted a retrospective review regarding the presence of inherited and 
acquired thrombophilia in this setting from January 2012 to November 2019. Tests 
included gene mutational analysis for Factor V Leiden, prothrombin G20210A, JAK2 exon 
12 – 15, Calreticulin (performed only if JAK2 mutation was negative) in addition to 
activated protein C resistance, antithrombin III, protein C and S levels, and 
antiphospholipid antibodies. Clinical, epidemiological, laboratory, and radiological data 
were collected. Patients were followed until death, liver transplantation, or end of the 
study (June 2020). 
Results: we included 77 patients with liver cirrhosis and non-malignant PVT in whom a 
thrombophilic study had been performed. Except for the screening of JAK2 V617 and 
calreticulin mutations which were only investigated in 20 patients, the remaining 
thrombophilic tests were available in the whole cohort. Four patients (5.2%) had a 
thrombophilic disorder: antiphospholipid syndrome in 2 patients, prothrombin gene 
mutation in 1 and factor V Leiden mutation in another patient. This latter patient was 
also diagnosed of polycythemia vera after detecting a JAK2 V617F mutation. Complete 
thrombosis of the main portal vein and rethrombosis after stopping anticoagulation were 
more frequent in patients with thrombophilia, but the rates of recanalization under 
anticoagulant therapy were similar among groups.  
Conclusions: the low prevalence of acquired and inherited thrombophilia found in 
patients with cirrhosis and PVT support testing for these disorders on an individual basis 
and avoiding universal screening to reduce costs and unwarranted testing. 
Abstract: 300 words. Key words: Liver cirrhosis, Portal vein thrombosis, Thrombophilia 
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RESUMEN 
Introducción: En los pacientes con cirrosis hepática, la contribución de los 
trastornos protrombóticos hereditarios y adquiridos en el  desarrollo de la 
TVP no maligna no es concluyente. El  propósito de este estudio fue 
examinar la prevalencia de la trombofi l ia hereditaria y adquirida en la TVP 
cirrótica no maligna en nuestro centro. Como objetivos secundarios 
exploramos la influencia de estos trastornos en la presentación cl ínica de 
la TVP y la respuesta a la anticoagulación. 
Métodos: real izamos una revisión retrospectiva sobre la presencia de 
trombofi l ia hereditaria y adquirida en este entorno desde enero de 2012 
hasta noviembre de 2019. Las pruebas incluyeron análisis de mutación 
genética para el  Factor V Leiden, protrombina G20210A, JAK2 exón 12 -  
15, Calreticul ina (real izado sólo si  la mutación JAK2 fue negativa) además 
de resistencia a la proteína C activada, niveles de antitrombina I I I ,  
proteína C y S,  y anticuerpos antifosfol ípidos. Se reunieron datos cl ínicos, 
epidemiológicos, de laboratorio y radiológicos. Se hizo un seguimiento de 
los pacientes hasta la muerte, el  trasplante de hígado o el  f inal  del estudio 
( junio de 2020). 
Resultados:  incluimos 77 pacientes con cirrosis hepática y PVT no maligna 
en los que se había realizado un estudio trombofí l ico. A excepción del 
análisis de JAK2 V617 y las mutaciones de calreticul ina, que sólo se 
investigaron en 20 pacientes, las pruebas trombofí l icas restantes estaban 
disponibles en toda la cohorte. Cuatro pacientes (5,2%) tenían un 
trastorno trombofí l ico: síndrome antifosfol ípido en 2 pacientes, mutación 
del gen de la protrombina en 1 y mutación del factor V Leiden en otro 
paciente. A este últ imo paciente también se le diagnosticó policitemia 
vera tras detectar una mutación JAK2 V617F. La trombosis completa de la 
vena porta principal y la retrombosis después de detener la 
anticoagulación fue más frecuente en los pacientes con trombofi l ia,  pero 
las tasas de recanalización bajo la terapia anticoagulante fueron similares 
entre los grupos.  
Conclusiones:  la baja prevalencia de trombofi l ia adquirida y hereditaria 
encontrada en pacientes con cirrosis y PVT apoya la realización de pruebas 
para estos trastornos de forma individual y evitar la detección universal  
para reducir los costos y las pruebas injustif icadas. 
Resumen: 347 palabras. Palabras clave: Cirrosis hepática, Trombosis de la 
vena porta, Trombofi l ia.  
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INTRODUCTION 
 
Non-malignant portal vein thrombosis (PVT) is defined as a thrombus that develops 
within the portal vein trunk and intrahepatic portal branches, which may also involve the 
splenic (SV) or superior mesenteric veins (SMV). In the absence of recanalization, the 
portal venous lumen is obliterated and portoportal collaterals develop resulting in portal 
cavernoma. The latter transformation is generally used to define the chronic stage of PVT 
(Figure 1) 1. It constitutes the most common thrombotic event in patients with cirrhosis, 
with increased rates in the setting of advanced liver disease. The reported prevalence of 
PVT varies with different diagnostic methods and target populations, ranging between 
approximately 10%-25% in patients with decompensated cirrhosis and 1%-5% in those 
with compensated cirrhosis 2.  Despite being a well-known complication of liver cirrhosis, 
the contribution of PVT to hepatic decompensation and overall mortality is still a matter 
of debate 1,3-5. Discrepancies among studies regarding patient selection criteria 
(compensated vs decompensated), degree and extent of thrombosis (occlusive vs 
nonocclusive), treatment strategies (anticoagulation vs no anticoagulation), sample size 
and time of follow-up have led to conflicting data 6. There is consequently no consensus 
on its optimal management and no definitive recommendations have been reported in 
clinical guidelines or consensus conferences 1,4,5,7,8. 
The mechanisms involved in the development of PVT in patients with cirrhosis are also 
not yet fully understood. Of the three pathophysiologic factors predisposing to 
thromboembolism described in the triad of Virchow (slow blood flow, endothelial 
damage and hypercoagulability), portal flow seems to be the most influential in the 
setting of cirrhosis 4. The efficacy of transjugular intrahepatic portosystemic shunt (TIPS) 
in restoring PVT patency by presumably increasing portal flow 1 and the identification of 
a reduced portal flow as a major risk factor for PVT development support this notion 9,10. 
Other potential mechanisms involved include a state of hypercoagulability in more 
advanced disease, bacterial translocation and inflammation, and vascular injury to the 
portal venous system secondary to several procedures (e.g. splenectomy) 3.  
Inherited and acquired prothrombotic disorders may also play a role, although current 
data are conflicting. The limited number of studies available are mostly case-control 
studies with small sample sizes. Their study design, target population (diverse ethnicities 
and geographical locations), diagnostic criteria for PVT, and assessment of thrombophilic 
conditions vary widely, and contribute to the inconsistent results (Table 1) 11-33. 
Moreover, none of these studies have properly evaluated whether the presence of 
thrombophilia impact the progression rate or response to treatment. Among the 
different thrombophilic genetic defects, Factor V Leiden (FVL) and prothrombin G20210A 
(PTHR) mutations have been the most frequently studied. Three meta-analysis concluded 
that they increased the risk of PVT in patients with cirrhosis 34-36, although in one of them 
this association was not shown for PTHR 35 and all of them are biased by the quality of 
the studies included. Inherited protein C, protein S or antithrombin III are difficult to 
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detect due to co-existent liver synthetic dysfunction 4. Their levels, however, do not seem 
to be associated with PVT development 37. The methylene tetrahydrofolate reductase 
(MTHFR) C677T and plasminogen activator inhibitor (PAI)– type 1 4G-4G mutations have 
also been described as independent predictors of PVT 18, although these polymorphisms 
have not been conclusively associated with increased thrombotic risk 38. The role of 
acquired prothrombotic disorders has been less evaluated in patients with liver cirrhosis 
and PVT. In contrast to non-cirrhotic PVT, the association between myeloproliferative 
disorders and antiphospholipid syndrome is so far inconclusive 3. Due to the conflicting 
data, current guidelines make no strong recommendation regarding testing for these 
conditions in either a screening capacity before PVT diagnosis or confirmatory once 
thrombosis has developed 1,4,7,8. 
 
AIMS 
 
The purpose of this study was to examine the prevalence of inherited and acquired 
thrombophilia in cirrhotic non-malignant PVT at our center. As secondary aims we 
explored the influence of these disorders on the clinical presentation of PVT and response 
to anticoagulation. 
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MATERIAL AND METHODS 
 
Patients 
The Marques de Valdecilla University Hospital (Santander, Cantabria, Spain) is an urban, 
academic tertiary care center. Since 2012 we began to test for thrombophilia in patients 
with cirrhosis who developed a non-malignant PVT. In this report, we conducted a 
retrospective review regarding the presence of inherited and acquired thrombophilia in 
this setting from January 2012 to November 2019. The identification of PVT cases was 
performed using three approaches: 1) Database from the Gastrointestinal and 
Hepatology Service; 2) Individual review of all thrombophilic studies performed during 
the study period by the Department of Hematology; 3) Hospital discharge records.  
Cirrhosis was confirmed on the basis of clinical, laboratory, and imaging studies or liver 
biopsy, and PVT was diagnosed as part of biannual screening for hepatocellular carcinoma 
(HCC) or during hospitalization for decompensated cirrhosis. Patients without 
thrombophilic study or with malignant PVT (i.e. presence of vascularization of the 
thrombus at contrast imaging, mass-forming features of PVT and/or evidence of 
disruption of vessel walls) were excluded. The presence of a cavernomatous 
transformation of the portal vein was not considered an exclusion criterion. 
Definitions 
PVT was defined as the absence of flow in part of or in the entire lumen of any site among 
portal vein trunk, portal vein branches, superior mesenteric vein (SMV) or splenic vein 
(SV) caused by the presence of solid material within the vein, as documented by an 
imaging technique (Doppler ultrasound [US], computed tomography [CT], or magnetic 
resonance imaging [MRI]). Thrombosis was considered complete when the blood flow 
was absent, or the thrombus involved more than 90% of the vessel diameter. Otherwise, 
it was defined as partial. Evolution of thrombosis was classified as previously reported by 
Delgado et al 39. Recanalization was considered complete when the portal vein trunk, 
portal vein branches, SMV, and SV were all completely patent. Recanalization was 
considered partial when some parts of the thrombus persisted but there was at least a 
50% reduction in the thickness or length of the thrombus, or when complete patency was 
achieved in the portal vein trunk and in at least one of the following segments if 
previously thrombosed: main intrahepatic branches, SV or SMV. Lack of recanalization 
according to the definition above was considered to be a non-response to treatment. 
Thrombosis progression was considered to occur when thrombus thickness 
increased>50% or when the thrombosis extended to previously unaffected segments of 
the spleno-porto-mesenteric axis.  
Anticoagulation therapy 
The decision to start and type of anticoagulation treatment was at the discretion of the 
 7 
physician taking care of the patient and was begun after initiation of appropriate primary 
or secondary prophylaxis of variceal bleeding. In general, full-dose low-molecular-weight 
heparin (LMWH) was started and switched after 4-6 weeks to vitamin k antagonists to 
maintain INR between 2 and 3. Patients with significantly prolonged INR in the setting of 
advanced liver cirrhosis were maintained with LMWH. Among patients receiving LMWH, 
factor Xa assay was not performed to verify the efficacy of anticoagulation.  
Follow up 
The date of first abdominal imaging study detecting PVT was considered as time zero for 
computing follow-up. Clinical, epidemiological, laboratory, and radiological data were 
collected at PVT diagnosis. Patients were followed until death, liver transplantation (LT), 
or end of the study (June 2020). Imaging follow-up was not performed according to a 
strict protocol, but at the discretion of the attending physicians. In general, it consisted 
of abdominal US and CT/MRI within 6 months of start of anticoagulation and then 
abdominal Doppler US every 6 months. The most recent follow-up imaging studies were 
used to evaluate PVT recanalization if performed at least 4 weeks after PVT diagnosis. All 
data was extracted from the electronic medical record. 
Thrombophilic study 
Test for thrombophilia were delayed until at least four weeks after PVT diagnosis, at 
which time LMWH were switched to vitamin K antagonists. Tests included gene 
mutational analysis for Factor V Leiden, prothrombin G20210A, JAK2 exon 12 – 15, 
Calreticulin (performed only if JAK2 mutation was negative) in addition to activated 
protein C resistance, antithrombin III, protein C and S levels, and antiphospholipid 
antibodies. The latter included anticardiolipin (aCL), antibeta2 glycoprotein (aB2GPI), and 
lupus anticoagulant (LA). The hypercoagulable panel was interpreted by Hematology, and 
the presence of liver cirrhosis was taken into consideration in all patients.  
Blood samples were collected in vacutainer tubes containing NaCitrate 3.2% in 1/9 
proportion. After centrifugation (2500 rpm), 1 ml aliquots were stored at -30ºC and used 
within 30 days. Protein C and antithrombin III were determined using automated 
chromogenic assay for quantitative determination on IL Coagulation Systems (HemosIL 
WerfenÒ). Free Protein S level was determined using an automated latex ligand 
immunoassay on IL Coagulation Systems (HemosIL WerfenÒ). Activated Protein C 
resistance was determined with coagulometric test based on TTPa parameter (HemosIL 
WerfenÒ). Normal values were established according to 100 control patients of the same 
age range and gender and were as follows: antithrombin, 85-140%; protein C, 85-140%; 
protein S, 70-120%. LA was determined using diluted Russell´s viper venom test and silica 
Cotting time (HemosIL WerfenÒ). Serum IgG and IgM aCL and aB2GPI levels were 
measured by ELISA following manufacturer’s instructions (Orgentec Diagnostika, Mainz, 
Germany) and expressed in GPL or MPL units or U/ml, respectively.  Titers were 
considered to be positive when they were above the 99th percentile, thus corresponding 
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to values above 20 GPL, MPL or U/ml (medium: 20-30 or high: >30 titers). If positive, they 
were repeated at least 12 weeks later in order to confirm their positivity. 
For genetic determinations, DNA was extracted from peripheral blood leukocytes 
according to standard protocols. Detection of JAK2 V617F, Prothrombin G20210A, and 
FVL G1691A mutation was performed using LightCyclerÒ 2.0 Real-Time PCR System 
(Roche Diagnostics, Mannheim, Germany). DNA extracted from HEL cells served as a 
positive control for the JAK2 V617F mutation. To assess the allelic burden of the JAK2 
V617F mutation in carriers, melting curves with dilution series using DNA from HEL cells 
were obtained and compared to the patient’s melting curve. Minimum allelic burden 
reliably detectable was 5 %.  
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki 
as reflected in a priori approval by the Ethics Committee for Clinical Research of 
Cantabria. A waiver of informed consent was provided since the study was considered a 
retrospective review. 
Statistical analysis  
Continuous variables were assessed by Kolmogorov-Smirnov test for normality and 
expressed as mean ± standard deviation (SD) or median and interquartile range. 
Categorical variables were expressed as counts and percentages. Comparisons between 
groups was performed using Student ś T test or Mann-Whitney U test for continuous 
variables and χ2 or Fisher ś exact test for categorical variables as applicable. Follow-up 
was calculated from the time of PVT diagnosis to the date of the last imaging study 
available before death, LT, or 1 June 2020. Statistical analysis was performed with IBM 
SPSS Statistics v22.0 for Mac (IBM Corp., Armonk, NY, United States).  
 
RESULTS 
Prevalence of thrombophilia 
During the study period, 166 cases of PVT were evaluated, of which 89 were excluded 
(Figure 2). The final cohort included 77 patients with liver cirrhosis and non-malignant 
PVT in whom a thrombophilic study had been performed. Except for the screening of 
JAK2 V617 and calreticulin mutations which were only investigated in 20 patients, the 
remaining thrombophilic tests were available in the whole cohort.  
Four patients (5.2%) had a thrombophilic disorder: antiphospholipid syndrome in 2 
patients, prothrombin gene mutation in 1 and factor V Leiden mutation in another 
patient. This latter patient was also diagnosed of polycythemia vera after detecting a JAK2 
V617F mutation. The remaining patients tested negative for JAK2 and calreticulin 
mutations. A detailed description of these four patients is provided in Table 2.  
Characteristics of patients with and without thrombophilia 
The clinical and epidemiological profile of patients with and without thrombophilia was 
similar (Table 3). Most patients had an alcoholic liver disease, were decompensated 
before PVT diagnosis and were on non-selective betablocker treatment in the setting of 
primary or secondary prophylaxis of variceal bleeding. Three patients, all in the non-
thrombophilic group, had suffered a previous arterial or venous thrombotic event 
(myocardial infarction in 1 patient, deep vein thrombosis in another, and pulmonary 
embolism in the remaining patient). 
Extension and clinical characteristics of thrombosis at diagnosis 
Diagnosis of PVT was made by CT or MRI in the majority of patients. The portal vein or its 
branches were the only thrombosed vessels in 50 patients (64.9%). In 2 patients (2.6%) 
the thrombosis extended to the SV, in 17 (22.1%) to the SMV, and in 4 patients (5.2%) it 
involved the entire splenoportomesenteric venous axis. Three patients (3.9%) had 
isolated thrombosis of the SMV and one (1.3%) of the SV. Portal cavernoma was 
established in nine patients (11.7%). In most cases, thrombosis was partial, regardless of 
its location. In patients with thrombophilia, however, complete thrombosis of the main 
portal vein and its right vein was more frequent in comparison to patients without 
thrombophilia (Table 4). Four patients, all in the non-thrombophilic group, had a local 
predisposing local factor. In all them PVT developed several weeks after radiofrequency 
ablation of HCC.  
Thirty-three patients (42.9%) showed new symptoms overlapping with the diagnosis of 
PVT. The most frequent decompensation event was variceal bleeding followed by hepatic 
encephalopathy. PVT only led to the development of mesenteric ischemia in one patient 
(1.5%). No differences in clinical presentation or analytical parameters were observed 
between patients with and without thrombophilia (Table 4). 
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Anticoagulation and Outcome of Thrombosis  
Five patients were excluded from this analysis. Four of them were participating in a 
randomized control trial to evaluate the effect of rivaroxaban in patients with advanced 
liver disease with PVT (Tromboxabab; EudraCT Number 2016-003240-37) and the other 
patient died soon after PVT diagnosis. In the remaining 72 patients, anticoagulation was 
frequently started (76.6%), while the placement of a TIPS was rare (5.2%) and always 
indicated by complications of cirrhosis, and not by progression of PVT (Table 5).  
Therapy was maintained with LMWH in 12 patients, with vitamin K antagonists in 46, and 
with apixaban in one patient. Median delay from PVT diagnosis to the beginning of 
anticoagulation treatment was 9 days (interquartile range, 0–42 days) and its median 
duration was 12.6 months (interquartile range, 6.2–27.0). Compared with untreated 
patients, those who received anticoagulation or TIPS more frequently achieved partial or 
total resolution of PVT (66.1% vs. 23.1%; p = 0.011). After ceasing anticoagulation, 
rethrombosis developed in ten patients (32.3%), with a trend for this event to occur more 
frequently in patients with thrombophilia (100% vs 27.6%; p=0.097). No other difference 
regarding treatment and outcome was observed between patients with and without 
thrombophilia (Table 5). 
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DISCUSSION 
 
In patients with liver cirrhosis, the contribution of inherited and acquired prothrombotic 
disorders in the development of non-malignant PVT is inconclusive. The limited available 
data is hampered by the heterogeneity and small sample size of the studies. The present 
report constitutes one of the largest series in this topic and, contrary to most published 
studies, includes a thorough thrombophilia workup. The interpretation of the 
hypercoagulable panel by Hematology is another strength of the present work as many 
previous studies do no to provide information in this regard. Our results show a very low 
prevalence of inherited and acquired thrombophilia in patients with cirrhotic non-
malignant PVT and question the utility of universal screening in this setting. 
The prevalence of thrombophilia in our cohort was similar to prevalence of these 
disorders in the general population 38 and is also in agreement with other previous 
reports that did not find an association between the presence of inherited or acquired 
thrombophilia and the risk of PVT in patients with liver cirrhosis 11,16,21,22,24,27,28,30,33,39. Of 
interest, although limited by the low number of patients with thrombophilia, complete 
thrombosis of the main portal vein and rethrombosis after stopping anticoagulation were 
more frequent in these patients. In contrast, the rates of recanalization under 
anticoagulant therapy were similar among groups and in keeping with those reported to 
date 40. Definite conclusions about the prevalence of prothrombotic disorders and the 
usefulness of their screening in this setting can neither be drawn from the findings of our 
study nor from the previously reported data due to the relatively small sample size. 
However, the available data together with associated healthcare costs support reserving 
these thrombophilia tests for patients with family histories of prothrombotic defects, 
patients with multiple sites of thrombosis, recurrent thrombosis, or when treatment 
decisions (i.e., anticoagulation duration) may be affected.  
The main limitations of our study are related to its retrospective and unicenter design. 
The relatively small sample size and the absence of a control group of patients with 
cirrhosis and without PVT should also be acknowledged. However, the overall 
interpretation of our results would probably not change given the low prevalence of 
thrombophilic disorders found in our cohort. Finally, JAK2 and calreticulin mutations were 
not performed in all patients as these tests were later included in the 
thrombophilia workup. 
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CONCLUSIONS 
 
We found a very low prevalence of acquired and inherited thrombophilia in patients with 
cirrhosis and PVT. Our results support testing for these disorders on an individual basis 
and avoiding universal screening to reduce costs and unwarranted testing. Future 
prospective studies integrating evaluation of liver disease stage, local and genetic factors 
are needed to identify individualized criteria to perform these tests and to evaluate their 
impact on the progression rate or response to treatment. 
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FIGURES 
 
Figure 1. Types of portal vein thrombosis according to the age of the 
thrombus. Taken from Intagliata et al 3   
 
 
 
 
 
  
hemostasis defects leading to venous (rarely arterial) throm-
bosis. Hypercoagulability is evident in both non-cirrhotic and
cirrhotic PVT, but is often dominated by different pathways.
Inherited genetic mutations, such as factor V Leiden and
prothrombin gene G20210A polymorphisms are more
common in patients with both cirrhotic8,9 and non-cirrhotic
PVT.10,11 These common mutations are relatively weak
pro-coagulant factors compared to inherited deficiencies of
anticoagulant factors, such as antithrombin, protein C (PC),
and protein S (PS). Among acquired thrombophilic condi-
tions, the anti-phospholipid syndrome is characterized by
persistent positivity of lupus anticoagulant and/or solid-
phase antibodies to cardiolipin or b2-glycoprotein-I.12
Deficiencies of the naturally occurring anticoagulants,13
high levels of procoagulant factors,14 or the presence of
the anti-phospholipid syndrome15–17 in patients with PVT
are reported. However, the phenotypic activity of naturally
occurring anticoagulants cannot be easily measured in
cirrhotic PVT due to impaired synthetic capacity of the liver.
Similarly, tests of lupus anticoagulants in anti-phospholipid
syndrome may be prolonged beyond the upper limit of the
reference range in cirrhosis. Moreover, the solid-phase an-
tibodies to cardiolipin or b2-glycoprotein-I have been
measured only sporadically in patients with PVT and not
according to the most recent standards.18 Thus, these
associations remain uncertain.
Evidence is accumulating that the rebalanced hemostasis
system in cirrhosis is prone to hypercoagulability, as
demonstrated by in vitro thrombin generation studies.19–21
This balance is mainly due to decreased levels of PC and
increased levels of factor VIII (FVIII).19,22,23 Activated PC is
the physiological inhibitor to FVIII, the latter being the most
potent driver of thrombin generation. Therefore, high
levels of FVIII, low levels of PC, and the FVIII/PC ratio are an
index of hypercoagulability in cirrhosis. These changes are
associated with unfavorable outcome in patients with
cirrhosis.24 Furthermore, patients with cirrhosis who are
resistant to the anticoagulant action of thrombomodulin
(in vitro) are more likely to develop de novo PVT.25
Thrombophilia may occur via other mechanisms,
including increased levels of circulating cell-derived micro-
particles containing negatively charged phospholipids or
tissue factor derived from the parent cells (eg, platelets or
monocytes). In addition, activated neutrophils in areas
of inflammation cause release of neutrophil external traps
that can increase thrombin generation without affecting
levels of the pro- or anticoagulant factors.26,27 Neutrophil
external traps have been associated with increased risk of
thrombosis in both non-cirrhotic subjects28,29 and in
cirrhosis.30 High levels of gut-derived bacterial lipopolysac-
charide are common in cirrhosis and could also contribute to
hypercoagulability31 and platelet hyperactivity.32
Isolated assessment of any of the individual components
of the Virchow’s triad is insufficient to entirely define
individual risk.25 Nonetheless, there are shared features
between cirrhotic and non-cirrhotic PVT beyond anatomical
Figure 1. Types of portal vein thrombosis.
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Figura 2. Flowchart of patients 
 
 
 
 
Abreviations: PVT: Portal vein thrombosis. 
 
Patients with portal vein thrombosis
N= 166
Patients included
N= 77
• Malignant PVT; N= 35
• No thrombophilic study; N= 32
• Non-cirrhotic PVT; N= 16
• Other; N= 16
TABLES 
 
Table 1. Large studies evaluating the prevalence of acquired and inherited thrombophilia in non-malignant portal vein 
thrombosis in patients with liver cirrosis. 
 
Author and 
year N** 
Study period 
and type Population PTHR FVL APS JAK2 MTHFR PAI Comments 
Mahmoud et 
al; 1997 32 
NS 
Retrospective 
UK - 
1/32 
(3.1%) 
- - - - 
Authors concluded FVL was not a major 
contributor of PVT. Not all 32 patients had liver 
cirrhosis.  
Amitrano et 
al; 2000 23 
1998-1999 
Case-control 
Italy 
8/23 
(34.8%) 
3/13 
(13%) 
0/23 
(0%) 
- 
10/23 
(43.5%) 
- 
PTHR and MTHFR were strongly associated with 
PVT. 
Amitrano et 
al; 2004 79 
1998-2002 
Case-control 
Italy 
15/70 
(21.4%) 
8/70 
(11.4%) 
0/70 
(0%) 
- 
15/70 
(21.4%) 
- 
ACA IgG and ACA IgM at low levels in PVT. PTHR 
increased more than fivefold the risk of PVT. 
Mangia et al; 
2005 
43 
1997-1999 
Case-control 
Italy 
2/43 
(4.7%) 
1/43 
(2.3%) 
- - 
9/43 
(20.9%) 
- 
PTHR, FVL and MTHFR were evenly distributed 
among patients with and without PVT. Authors 
concluded they were not causative of PVT 
Amitrano et 
al; 2006 78 
1998-2002 
Case-control 
Italy 
17/78 
(21.4%) 
- - - - - 
PTHR was associated with PVT, and factor II 
levels were higher in patients with PTHR and 
PVT 
Pasta et al; 
2006 
78 
2000-2005 
Case-control 
Italy - - - - 
19/78 
(24.4%) 
- MTHFR was associated with PVT development.  
Colaizzo et al; 
2008 
91 
NS 
Retrospective 
Italy - - - 
5/91 
(5.5%) 
- - 
Intestinal infarction and previous thrombosis 
were more frequent in patients harboring JAK2. 
Authors suggested to search for JAK2 in the 
setting of severe PVT, previous thrombosis and 
no thrombopenia 
Gabr et al; 
2010 
21 
NS 
Case-control 
Egypt - - - - 
7/21 
(33%) 
- 
Authors concluded that MTHFR was associated 
with an increased risk of PVT. 
Amitrano et 
al; 2011 50 
NS 
Case-control 
Italy - - 
0/50 
(0%) 
- - - 
Antiphospholipid antibodies played no role in 
PVT associated with liver cirrhosis  
 20 
Author and 
year N** 
Study period 
and type Population PTHR FVL APS JAK2 MTHFR PAI Comments 
Ayala et al; 
2012 
50 
2001-2006 
Case-control 
Spain 
1/49 
(2%) 
1/49 
(2%) 
- 
0/50 
(0%) 
7/48 
(14.6%) 
- 
No association was observed between pre-
transplant PVT and presence of genetic 
thrombophilia  
Delgado et al; 
2012 
43 
2003-2010 
Retrospective 
Spain 
3/43 
(7%) 
1/43 
(2.3%) 
1/43 
(2.3%) 
- - - 
Multicenter study. Thrombophilia in 16% of 
patients and it was not associated with response 
to anticoagulation. Deficiency of protein S, C and 
antithrombin in 2, 1, and 1 patient, respectively.   
Qi et al; 
2012 
71 
2009-2011 
Prospective 
China - - - 
1/71 
(1.4%) 
- - 
Prevalence very close to that of a Chinese 
hospital population of patients without PVT. 
Senzolo et al; 
2012 
56 
2007-2008 
Prospective 
UK, Italy 
4/56 
(7%) 
2/56 
(3.6%) 
0/56 
(0%) 
- - - 
Bicenter study. One patient had combined 
thrombophilia (FVL + PTHR). 
Werner et al; 
2013 
69 
2005-2011 
Retrospective 
USA 
0/22 
(0%) 
0/22 
(0%) 
0/22 
(0%) 
- - - One patient had antithrombin deficiency. 
Karakose et al; 
2015 
38 
2005-2009 
Prospective 
Turkey 
4/38 
(10.5%) 
5/38 
(13.1%) 
- 
1/38 
(2.6%) 
5/38 
(13.2%) 
- Unicenter study.  
Nery et al; 
2015 
67 
2000-2006 
RCT 
France NS NS - - - - 
Multicenter RCT. PTHR and FVL were studied in 
283 patients, 67 of whom developed PVT. Their 
presence was not associated with PVT 
Saugel et al; 
2015 
21 
2009-2011 
Case-control 
Germany 
0/21 
(0%) 
1/21 
(4.8%) 
- 
2/21 
(9.5%) 
- - 
There was a trend for higher frequency of JAK2 
mutation in cirrhotic patients with PVT than 
those without PVT. 
Lancelloti et 
al; 2016 24 
2013 
Case-control 
Italy 
1/24 
(4.2%) 
0/24 
(0%) 
NS - - - 
PTHR and FVL were infrequent and not 
associated with PVT development 
Pasta et al; 
2016 
350 
2000-2014 
Prospective 
Italy 
18/350 
(5%) 
29/350 
(8%) 
- - 
88/350 
(25%) 
111/350 
(31%) 
Individual patient data from 3 prospective 
studies. At least one thrombophilic genetic 
factor was present in 54% of patients. MTHFR 
and PAI were associated with PVT.  
Ventura et al; 
2016 
38 
2009-2013 
Case-control 
Italy 
11/38 
(10.5%) 
4/38 
(10.5%) 
2/38 
(5.2%) 
- 
13/38 
(34.2) 
- 
PTHR and hyperhomocysteinemia were 
associated with PVT development 
Artaza et al; 
2018 
32 
2009-2015 
Retrospective 
Spain 
0/24 
(0%) 
2/24 
(8.3%) 
 
1/24 
(4.2%) 
- - 
Thrombophilia in 4 patients (16%). Elevated 
homocysteine in 1/24 (4.2%). No association 
between thrombophilia and evolution of PVT 
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Author and 
year N** 
Study period 
and type Population PTHR FVL APS JAK2 MTHFR PAI Comments 
Senzolo et al; 
2018 
149 
2008-2012 
Prospective 
International 
7/64 
(10.9%) 
7/71 
(9.9%) 
- 
1/32 
(3.1%) 
- - 
Centers from Europe, Canada and Korea. 
Thrombophilia testing in less than 50% of the 
patients. Authors did not search for an 
association between PVT and thrombophilia. 
Cagin et al; 
2019 
98 
2009-2015 
Case-control 
Turkey 
15/98 
(15.3%) 
12/98 
(12.2%) 
- - 
16/98 
(16.3%) 
- 
FVL mutation was the only type of 
thrombophilia associated with PVT. Reduced 
levels of protein C, S and AT-III: 74.4%, 72.4% 
and 64.2%. 
Tremblay et 
al, 2020 73 
2000-2019 
Retrospective 
USA 
4/63 
(6.3%) 
4/65 
(6.1%) 
2/66 
(3%) 
1/45 
(2.2%) 
1/27 
(3.7%) 
20/34 
(58.8%) 
Thrombophilia testing was not complete in most 
patients and infrequently led to change in 
management. No patient had PNH, protein C, S 
or AT-III deficiency or MPL and CALR mutations 
* The minimum number of patients with portal vein thrombosis to consider a study as large was 20. 
** Denotes the number of patients that developed portal vein thrombosis within each study, not to the total cohort in each of them.  
*** Percentages are calculated based on the number of patients tested for each type of thrombophilia, not the total cohort. 
Abbreviations: ACA: anti-cardiolipin antibodies; APS: antiphospholipid syndrome; AT-III: antithrombin III; FVL: factor V Leiden; JAK2: Janus Kinase 2 mutation; MTHFR: 
methylenetetrahydrofolate reductase TT677 genotype; PAI-1: plasminogen activator inhibitor type 1; PNH: paroxysmal nocturnal hemoglobinuria; PTHR: Prothrombin 
G20210A mutation; PVT: portal vein thrombosis; RCT: randomized control trial; UK: United Kingdom. 
 
Table 2. Clinical, imaging, endoscopic and laboratory features of patients with thrombophilia 
 
Variable * Case 1 Case 2 Case 3 Case 4 
Type of thrombophilia 
APS APS PV + FVL 
(heterozygous) 
PTHR 
(heterozygous) 
Age (years) 51 77 72 69 
Gender Female Male Male Male 
Race Caucasian Caucasian Caucasian Caucasian 
Comorbidity Diabetes  Diabetes  Diabetes  Diabetes  
Etiology of liver disease Hepatitis C Alcohol Alcohol Alcohol 
Child-Pugh  B (7 points) B (7 points) B (7 points) A (6 points) 
MELD (points) 11 9 12 11 
Previous variceal bleeding  Yes No No Yes 
EV without bleeding  High risk High risk  
Non-selective betablockers Yes Yes No Yes 
Previous ascites  Yes Yes No Yes 
Previous SBP No No No No 
Previous HE  Episodic No No Episodic 
Previous decompensation Yes Yes No Yes 
HCC (No/BCLC stage) No No No A 
Previous thrombotic events No No No No 
Imaging for PVT diagnosis CT US US CT 
Localization and extension 
Main PV / 
Complete 
Main PV / Partial PV and branches / 
Complete 
Right hepatic vein / 
Complete 
Portal cavernoma Yes No No No 
Local predisposing factor No No No No 
Decompensation at diagnosis 
Ascites EV bleeding and 
ascites 
Ascites No 
Other symptoms No No No No 
Analytical parameters at diagnosis     
Leucocytes (x103 μL) 3.4 5.1 2.3 5.0 
 Platelets (x103 μL) 60 140 65 162 
 Hemoglobin (gr/dL) 9.8 11.6 11 13.9 
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Variable * Case 1 Case 2 Case 3 Case 4 
 Creatinine (mg/dL) 0.96 0.97 0.88 0.85 
 Sodium (mEq/L) 138 134 138 137 
 ALT (U/L) 56 44 62 26 
 AP (U/L) 119 235 47 123 
 Bilirubin (mg/dL) 0.9 1.2 2.1 1.4 
 Albumin (gr/dL) 2.9 3.2 4.2 3.8 
 INR 1.45 1.14 1.34 1.27 
Treatment Acenocoumarol Acenocoumarol LMWH No 
PVT evolution Progression Partial resolution Total resolution Stability 
Rethrombosis   Yes Yes  
Exitus/LT LT Death Death LT 
Time of follow-up (months) 21.3 16.9 85.0 24.0 
* Quantitative variables were expressed as median and interquartile range and qualitative variables as absolute value (proportion). 
Abbreviations: ALT: alanine aminotransferase; AP: Alkaline phosphatase, APS: antiphospholipid syndrome; BCLC: Barcelona Clinic Liver 
Cancer; CT: computed tomography; EV: esophageal varices; HCC: hepatocellular carcinoma; INR: international normalized ratio; LMWH: 
low-molecular-weight heparin; LT: liver transplantation; MELD: Model for End-Stage Disease; PV: polycythemia vera; PVT: portal vein 
thrombosis; TIPS: Transjugular intrahepatic portosystemic shunt, US: ultrasound. 
 
 
Table 3. Clinical and epidemiological profile of patients in the whole cohort and in patients with and without 
thrombophilia 
 
Variable * Population  
(N= 77) 
Non-thrombophilia 
(N=73) 
Thrombophilia 
(N=4) 
p 
Age (years) 61.9 (55.0-67.6) 61.7 (55.0-67) 70.6 (55.5-76.0) 0.160 
Gender (male) 67 (87) 64 (87.7) 3 (75.0) 0.434 
Race (Caucasian) 76 (98.7) 72 (98.6) 4 (100) 1 
Diabetes Mellitus 24 (31.2) 20 (27.4) 4 (100) 0.008 
Dyslipemia 12 (15.6) 12 (16.4) 0 (0) 1 
Arterial hypertension 22 (28.6) 22 (30.1) 0 (0) 0.320 
Chronic kidney injury 5 (6.5) 5 (6.8) 0 (0) 0.961 
HIV 4 (5.2) 4 (5.5) 0 (0) 1 
Etiology of liver disease    0.979 
 Alcohol 49 (63.6) 46 (63.0) 3 (75)  
 Hepatitis C 8 (10.4) 7 (9.6) 1 (25)  
 Alcohol + hepatitis C 9 (11.7) 9 (12.3) 0 (0)  
 Other 11 (14.3) 11 (15.1) 0 (0)  
Child-Pugh (points) 7 (6-9) 7 (6-9) 7 (6-7) 0.279 
Child A/B/C (%) 35 / 50 / 15 36 / 49 / 15 1 / 3 / 0 0.530 
MELD (points) 12 (10-14) 13 (10-14) 11 (10-12) 0.283 
Previous TIPS 4 (5.2) 4 (5.5) 0 (0) 1 
Liver allograft cirrhosis 3 (3.9) 3 (4.1) 0 (0) 1 
Esophageal varices (Low/High risk) 14 (32) / 22 (50) 14 (33.3) / 20 (47.6) 0 (0) / 2 (50) 0.351 
Previous variceal bleeding  33 (42.9) 31 (42.5) 2 (50) 1 
Non-selective betablockers 51 (66.2) 48 (65.8) 3 (75) 1 
Previous ascites (No/Yes/Refractory) 
(%) 
27 / 65/ 8 28 /64 / 8 25 / 75 / 0 0.818 
Previous SBP 6 (7.8) 6 (8.2) 0 (0) 1 
Previous HE (No/Episodic/Recurrent) 
(%) 
75 / 24 / 1 77 / 22 / 1 2 / 2 / 0 0.429 
Any previous decompensation 62 (80.5) 59 (80.8) 3 (75) 1 
HCC (No/BCLC stage A /B) (%) 87 / 12 / 1 88 / 11 / 1 3 / 1 / 0 0.682 
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Variable * Population  
(N= 77) 
Non-thrombophilia 
(N=73) 
Thrombophilia 
(N=4) 
p 
Previous abortions 0 (0) 0 (0) 0 (0)  
Previous arterial/venous thrombotic 
events 
3 (3.9) 3 (4.1) 0 (0) 1 
* Quantitative variables were expressed as median and interquartile range and qualitative variables as absolute value 
(proportion). 
Abbreviations: BCLC: Barcelona Clinic Liver Cancer; HCC: hepatocellular carcinoma; HE: hepatic encephalopathy; HIV: human 
immunodeficiency virus; MELD: Model for End-Stage Disease; SBP: spontaneous bacterial peritonitis; TIPS: Transjugular 
intrahepatic portosystemic shunt 
Table 4. Extension and clinical characteristics of portal vein thrombosis at diagnosis in the whole cohort and in patients 
with and without thrombophilia 
 
Variable * Population  
(N= 77) 
Non-thrombophilia 
(N=73) 
Thrombophilia 
(N=4) 
p 
CT or MRI for PVT diagnosis 67 (87.0) 65 (89) 2 (50) 0.080 
Localization and extension      
 Right PV (Partial/total) (%) 27 (35.1) / 8 (10.4) 27 (37.0) / 6 (8.2) 0 (0) / 2 (50) 0.020 
 Left PV (Partial/total) (%) 18 (23.4) / 5 (6.5) 17 (23.3) / 5 (6.8) 1 (25) / 0 (0) 0.864 
 Main PV (Partial/total) (%) 49 (63.6) / 8 (10.4) 48 (65.8) / 6 (8.2) 1 (25) / 2 (50) 0.025 
 SV (Partial/total) (%) 5 (6.5) / 2 (2.6) 5 (6.8) / 2 (2.7) 0 (0) / 0 (0) 0.810 
 SM vein (Partial/total) (%) 21 (27.3) / 3 (3.9) 21 (28.8) / 3 (4.1) 0 (0) / 0 (0) 0.385 
Portal cavernoma 9 (11.7) 8 (11) 1 (25) 0.398 
Local predisposing factor 4 (5.2) 4 (5.4) 0 (0) 1 
Symptoms at diagnosis 33 (42.9) 32 (43.8) 1 (25) 0.631  
 Acute mesenteric ischemia 1 (1.3) 1 (1.4) 0 (0) 1 
 Abdominal pain 7 (9.1) 7 (9.6) 0 (0) 1 
 Fever 2 (2.6) 2 (2.7) 0 (0) 1 
 Variceal bleeding 14 (18.2) 13 (17.8) 1 (25) 0.560 
 Ascites (total/de novo) 38 (49.4) / 5 (6.5)   0.358 
 SBP 6 (7.8) 6 (8.2) 0 (0) 1 
 HE 10 (13.0) 10 (13.7) 0 (0) 1 
Analytical parameters at diagnosis     
 Leucocytes (x103 μL) 5.0 (3.3-6.0) 5.0 (3.3-6.1) 4.2 (2.6-5.1) 0.376 
 Platelets (x103 μL) 79 (62-110) 79 (62-108) 103 (61-157) 0.455 
 Hemoglobin (gr/dL) 12.8 (10.4-14.4) 12.8 (10.4-14.4) 11.3 (10.1-13.3) 0.532 
 Creatinine (mg/dL) 0.8 (0.7-1.0) 0.8 (0.7-1.0) 0.9 (0.8-1) 0.826 
 Sodium (mEq/L) 139 (137-141) 139 (137-141) 137 (135-138) 0.455 
 ALT (U/L) 34 (23-46) 34 (22-44) 50 (31-61) 0.747 
 Alkaline phosphatase (U/L) 114 (78-154) 110 (78-154) 121 (65-207) 0.931 
 Bilirubin 1.6 (1.1-2.5) 1.6 (1.1-2.7) 1.3 (1.0-1.9) 0.398 
 Albumin (gr/dL) 3.4 (3.0-3.8) 3.4 (3.0-3.8) 3.5 (3.0-4.1) 0.678 
 INR 1.34 (1.23-1.52) 1.34 (1.23-1.53) 1.31 (1.17-1.42) 0.376 
 27 
* Quantitative variables were expressed as median and interquartile range and qualitative variables as absolute value 
(proportion). 
Abbreviations: ALT: alanine aminotransferase; CT: computed tomography; INR: international normalized ratio; MRI: magnetic 
resonance imaging; PVT: portal vein thrombosis; SM: superior mesenteric vein; SV, splenic vein. 
Table 5. Treatment and outcome of portal vein thrombosis in the whole cohort and in patients with and without 
thrombophilia 
 
Variable * Population  
(N= 77) 
Non-thrombophilia 
(N=73) 
Thrombophilia 
(N=4) 
p 
Anticoagulation 59 (76.6) 56 (80) 3 (75) 1 
 Acenocoumarol 46 (78.0) 44 (78.6) 2 (66.7) 0.832 
 LMWH 12 (20.3) 11 (19.6) 1 (33.3)  
 Apixaban 1 (1.7) 1 (1.8) 0 (0)  
 Duration (months) 12.6 (6.2-27.0) 12.1 (6.0-25.3) 22.2 (8.1-157.2) 0.476 
TIPS  4 (5.2) 4 (5.5) 0 (0) 1 
PVT evolution    0.744 
 Stability 22 (30.5) 21 (30.9) 1 (25)  
 Progression 8 (11.1) 7 (10.3) 1 (25)  
 Partial resolution 12 (16.6) 11 (16.2) 1 (25)  
 Total resolution 30 (41.7) 29 (42.6) 1 (25)  
Rethrombosis after ceasing 
anticoagulation 
10 (32.3) 8 (27.6) 2 (100) 0.097 
Exitus 37 (48.1) 35 (47.9) 2 (50) 180 
Liver transplantation 17 (22.1) 15 (20.5) 2 (50) 0.210 
Time of follow-up (months) 27.0 (10.9-55.5) 27.5 (10.8-55.5) 22.7 (18.0-69.7) 0.995 
* Quantitative variables were expressed as median and interquartile range and qualitative variables as absolute value 
(proportion). 
Abbreviations: LMWH: low-molecular-weight heparin; PVT: portal vein thrombosis; TIPS: Transjugular intrahepatic 
portosystemic shunt 
 
